By VALIDOGEN GmbH
To get in touch with VTU Technology presenting broadest Pichia pastoris protein production toolbox at BIO Europe Spring 2017, simply fill out the form below.
Subscribe to Supplier
VTU Technology presenting broadest Pichia pastoris protein production toolbox at BIO Europe Spring 2017
Grambach, Austria: Protein production specialist VTU Technology will present significant advances in exploiting its leading Pichia pastoris recombinant expression technology at BIO-Europe Spring biotechnology partnering conference in Barcelona from March 20.
These include the use of VTU´s well-established Pichia protein production toolbox to facilitate high-yield production of nearly all kind of proteins in unmatched quantities and at reduced production costs.
VTU will present its productive Pichia toolbox outstanding through its broad genetic diversity significantly boosting protein yields and protein quality by fine-tuning of protein expression. Optimized tools for the humanization of Pichia´s glycosylation pathway enabling the directed production of glycoproteins with defined glycosylation profiles complement the broad toolbox.
VTU will also emphasize the advantages of its unique AOX1 based methanol-free protein production and expression processes.
VTU Technology Head of Business Development, Dr. Thomas Purkarthofer will lead the company’s presence in Barcelona, offering VTU´s broad contract services as well as out-licensing and co-development opportunities for several recombinant proteins based on the Pichia pastoris platform.
“We attend numerous partnering events, which provides us with a great platform to present our exclusive Pichia pastoris protein production technology and expertise to a wide range of customers from pharma-, biopharma-, food-, feed-, chemical-, agro-, cosmetic- and diagnostic sectors,” commented Dr. Purkarthofer.
“More than ever, we can show how VTU Technology’s broad Pichia pastoris protein production toolbox establishes economically viable protein production processes,” he added.
Since foundation in 2008, VTU has been continuously optimizing and expanding its Pichia technology platform to generate an unparalleled spectrum of expression tools and ingenious expression strategies to meet highly specific expression needs, leading to more flexibility in protein production.
With exclusive tools, VTU addresses the multiple aspects of protein production by providing myriad ways to meet customer´s requirements with contract services that include time-saving protein expression studies, development of industrial production strains, fermentation process development and optimization, protein sample purification and downstream process development and technology transfer. Moreover, preparation and characterization of research cell banks and high-throughput enzyme engineering services complement VTU´s broad service offerings.
About VTU Technology
VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. VTU develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins.
Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science. The VTU group currently counts more than 420 highly qualified people working in several subsidiaries in different European countries. From 2013 to 2015, the VTU group was able to boost its turnover from 40 million euros to 72 million euros. More information: www.vtu-technology.com and www.vtu.com
About BIO-Spring 2017
The BIO-Europe Spring® Conference (BIO Spring) is the springtime counterpart to EBD Group’s flagship conference BIO-Europe®, providing life science companies with further high caliber knowledge sharing and partnering opportunities.
The 2017 Bio-Europe Spring event is a three-day event opening March 20 at the CCIB Convention Centre in Barcelona, Spain.
The BIO-Europe partnering conferences have been running since 2006 and consistently attract top international executives from established and emerging pharma and biotech companies, along with academic researchers and private investors including venture capital and private equity and organizations developing companion diagnostics.
More than 2,400 delegates, the majority from boardroom level, are expected to attend BIO Spring 2017, representing some 1,400 companies from over 45 countries. The event will host more than 12,500 one-to-one meetings, with some 3,500 licensing opportunities posted.
The event is organized by EBD Group with more information at: https://ebdgroup.knect365.com/bioeurope-spring